Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.83 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.83 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.83 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.83 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12555287 | 1.00 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL12879424 | 0.93 | OPRM1 (0.80) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL19367978 | 0.91 | OPRM1 (0.85) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL19367933 | 0.91 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL5953724 | 0.91 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL25348849 | 0.91 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL12188165 | 0.91 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL49578 | 0.91 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL14995531 | 0.91 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL19367975 | 0.91 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381721-B2 | Substituted piperidine compounds | ADOLOR CORPORATION (US) | 2008-06-03 | — | — | US | claimed |
| US-8404693-B2 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110144108-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-06-16 | — | — | US | disclosed |
| US-7884102-B2 | opioid receptors antagonists such as 3-(3R,4R-dimethyl-piperidin-4-yl)-benzoic acid, used as analgesics or for the treatment of gastrointestinal disorders or side effect associated with an opioids | ADOLOR CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080306071-A1 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-7381721-B2 | Substituted piperidine compounds | ADOLOR CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| WO-2004082623-A2 | SUBSTITUTED PIPERIDINE COMPOUNDS | ADOLOR CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186135-A1 | Substituted piperidine compounds | CUBIST PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186135-A1 | Substituted piperidine compounds | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRD1 2/4885OPRK1 1/4885 |
| US-20080306071-A1 | Substituted piperidine compounds and methods of their use | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20110144108-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.